Synopsis: Pharma stock is in focus following the deal where promoter Ravi Agrawal Trust sold 34.5 lakh shares (2.8% stake) worth ₹1,024 crore at ₹2,968 each. Kotak Mahindra Mutual Fund bought 21 lakh shares for ₹624 crore, and Aditya Birla Sun Life Mutual Fund acquired 13.5 lakh shares for ₹400 crore.
The shares of a Mid-Cap company, specialising in the development, manufacturing, and marketing of high-quality speciality branded generics and generic pharmaceuticals, are in the spotlight after promoter sold shares worth Rs. 1,024 crore.
With a market capitalization of Rs. 38,217.18 crores in the day’s trade, the shares of Ajanta Pharma Ltd rose upto 1.9 percent, making a high of Rs. 3,070.35 per share compared to its previous closing price of Rs. 3,012.15 per share.
What Happened
Ajanta Pharma Ltd, engaged in the development, manufacturing, and marketing of high-quality speciality branded generics and generic pharmaceuticals, has announced a significant block deal involving its shares.
The company’s promoter entity, Ravi Agrawal Trust, sold 34.5 lakh shares, representing a 2.8 percent stake, for about Rs. 1,024 crore. Kotak Mahindra Mutual Fund acquired 21 lakh shares worth Rs. 624 crore, while Aditya Birla Sun Life Mutual Fund purchased 13.5 lakh shares valued at Rs. 400 crore. The transaction was executed at an average price of Rs. 2,968 per share.
Financials & Others
The company’s revenue rose by 21.47 percent from Rs. 1,170 crores in March 2025 to Rs. 1,422 crores in March 2026. Meanwhile, Net profit rose from Rs. 225 crores to Rs. 267 crores in the same period.
The company shows strong financial efficiency with a Return on Capital Employed (ROCE) of 32.3% and a Return on Equity (ROE) of 25.4%, indicating effective use of capital and strong profitability. It also maintains a very low debt-to-equity ratio of 0.06, reflecting minimal leverage and a strong, conservative balance sheet.
For FY26, capex is guided at Rs. 330 crore, in line with management expectations. For FY27, it is expected to increase to around Rs. 400 crore, including Rs. 150 crore for maintenance and Rs. 250 crore for growth capex at existing sites where adequate land is already available for expansion.
Management has guided for “high teens” topline growth, estimated at around 16–18 percent at current foreign exchange rates. This indicates steady business momentum supported by expansion plans and operational stability, providing clear visibility on medium-term growth performance.
Ajanta Pharma Ltd is an Indian speciality pharmaceutical company focused on developing, manufacturing, and marketing a wide range of finished dosages. It was established in 1973 and is headquartered in Mumbai, India. The company has a strong presence in branded generics, particularly in emerging markets across Asia, Africa, and India.
It is known for its focus on therapeutic areas such as cardiology, dermatology, ophthalmology, and pain management. It has built a reputation for offering niche, differentiated products rather than competing only in high-volume generic segments. The company also invests significantly in research and development to support its pipeline of speciality formulations and fixed-dose combinations.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
